Dynamiker GM Assays showed a good result in clinical contrast trial in Brazil

A few days ago, Dynamiker Aspergillus Galactomannan Assay has passed the stringent test of the biggest Hematonosis Hospital in Brazil which is also the blood disease and organ transplant centre in Latin America. Meanwhile, a contrast test has been conducted with Bio-Rad Platerlia Aspergillus EIA which was granted FDA approval.

The tested serum samples from 58 haematological patients with neutropenia. They were divided into three groups according to the standard of EORTC/MSG, the first group are none IA (check group), the second group are probable IA cases, the third group are proven IA cases.

The experimental result shows that the sensitivity for proven/probable IA is 81.8% and 77.8%, respectively. The final sensitivity is 79.3% and the specificity is 80.5%, the products also have good repeatability.

Dynamiker GM assays showed fair and good agreement with the Bio-Rad Platelia Aspergillus EIA, it also has been widely acknowledged and recognized by foreign peer experts which laid the solid foundation for further developing the South American market by Dynamiker.